Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1957 1
1962 1
1963 1
1965 4
1980 1
1981 2
1982 1
1983 3
1984 4
1985 3
1986 1
1987 1
1988 1
1989 3
1990 5
1991 4
1992 1
1993 6
1994 12
1995 4
1996 8
1997 9
1998 14
1999 13
2000 15
2001 13
2002 17
2003 32
2004 31
2005 46
2006 30
2007 66
2008 82
2009 70
2010 84
2011 89
2012 94
2013 88
2014 120
2015 114
2016 133
2017 148
2018 139
2019 139
2020 139
2021 2
Text availability
Article attribute
Article type
Publication date

Search Results

1,630 results
Results by year
Filters applied: . Clear all
Page 1
Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial.
Mok TSK, Wu YL, Kudaba I, Kowalski DM, Cho BC, Turna HZ, Castro G Jr, Srimuninnimit V, Laktionov KK, Bondarenko I, Kubota K, Lubiniecki GM, Zhang J, Kush D, Lopes G; KEYNOTE-042 Investigators. Mok TSK, et al. Among authors: wu yl. Lancet. 2019 May 4;393(10183):1819-1830. doi: 10.1016/S0140-6736(18)32409-7. Epub 2019 Apr 4. Lancet. 2019. PMID: 30955977 Clinical Trial.
TMPRSS2: A potential target for treatment of influenza virus and coronavirus infections.
Shen LW, Mao HJ, Wu YL, Tanaka Y, Zhang W. Shen LW, et al. Among authors: wu yl. Biochimie. 2017 Nov;142:1-10. doi: 10.1016/j.biochi.2017.07.016. Epub 2017 Aug 1. Biochimie. 2017. PMID: 28778717 Free PMC article. Review.
Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial.
Wu YL, Cheng Y, Zhou X, Lee KH, Nakagawa K, Niho S, Tsuji F, Linke R, Rosell R, Corral J, Migliorino MR, Pluzanski A, Sbar EI, Wang T, White JL, Nadanaciva S, Sandin R, Mok TS. Wu YL, et al. Lancet Oncol. 2017 Nov;18(11):1454-1466. doi: 10.1016/S1470-2045(17)30608-3. Epub 2017 Sep 25. Lancet Oncol. 2017. PMID: 28958502 Clinical Trial.
Biomarker for personalized immunotherapy.
Liu SY, Wu YL. Liu SY, et al. Among authors: wu yl. Transl Lung Cancer Res. 2019 Nov;8(Suppl 3):S308-S317. doi: 10.21037/tlcr.2019.08.02. Transl Lung Cancer Res. 2019. PMID: 31857954 Free PMC article. Review.
ADAURA: Phase III, Double-blind, Randomized Study of Osimertinib Versus Placebo in EGFR Mutation-positive Early-stage NSCLC After Complete Surgical Resection.
Wu YL, Herbst RS, Mann H, Rukazenkov Y, Marotti M, Tsuboi M. Wu YL, et al. Clin Lung Cancer. 2018 Jul;19(4):e533-e536. doi: 10.1016/j.cllc.2018.04.004. Epub 2018 May 1. Clin Lung Cancer. 2018. PMID: 29789220 Free article. Clinical Trial.
Osimertinib in Resected EGFR-Mutated Non-Small-Cell Lung Cancer.
Wu YL, Tsuboi M, He J, John T, Grohe C, Majem M, Goldman JW, Laktionov K, Kim SW, Kato T, Vu HV, Lu S, Lee KY, Akewanlop C, Yu CJ, de Marinis F, Bonanno L, Domine M, Shepherd FA, Zeng L, Hodge R, Atasoy A, Rukazenkov Y, Herbst RS; ADAURA Investigators. Wu YL, et al. N Engl J Med. 2020 Oct 29;383(18):1711-1723. doi: 10.1056/NEJMoa2027071. Epub 2020 Sep 19. N Engl J Med. 2020. PMID: 32955177 Clinical Trial.
Effects of Non-Vitamin K Antagonist Oral Anticoagulants Versus Warfarin in Patients With Atrial Fibrillation and Valvular Heart Disease: A Systematic Review and Meta-Analysis.
Pan KL, Singer DE, Ovbiagele B, Wu YL, Ahmed MA, Lee M. Pan KL, et al. Among authors: wu yl. J Am Heart Assoc. 2017 Jul 18;6(7):e005835. doi: 10.1161/JAHA.117.005835. J Am Heart Assoc. 2017. PMID: 28720644 Free PMC article. Review.
Improvement in Overall Survival in a Randomized Study That Compared Dacomitinib With Gefitinib in Patients With Advanced Non-Small-Cell Lung Cancer and EGFR-Activating Mutations.
Mok TS, Cheng Y, Zhou X, Lee KH, Nakagawa K, Niho S, Lee M, Linke R, Rosell R, Corral J, Migliorino MR, Pluzanski A, Sbar EI, Wang T, White JL, Wu YL. Mok TS, et al. Among authors: wu yl. J Clin Oncol. 2018 Aug 1;36(22):2244-2250. doi: 10.1200/JCO.2018.78.7994. Epub 2018 Jun 4. J Clin Oncol. 2018. PMID: 29864379 Clinical Trial.
A comprehensive review of uncommon EGFR mutations in patients with non-small cell lung cancer.
Tu HY, Ke EE, Yang JJ, Sun YL, Yan HH, Zheng MY, Bai XY, Wang Z, Su J, Chen ZH, Zhang XC, Dong ZY, Wu SP, Jiang BY, Chen HJ, Wang BC, Xu CR, Zhou Q, Mei P, Luo DL, Zhong WZ, Yang XN, Wu YL. Tu HY, et al. Among authors: wu yl. Lung Cancer. 2017 Dec;114:96-102. doi: 10.1016/j.lungcan.2017.11.005. Epub 2017 Nov 7. Lung Cancer. 2017. PMID: 29173773 Review.
Emerging therapies for non-small cell lung cancer.
Zhang C, Leighl NB, Wu YL, Zhong WZ. Zhang C, et al. Among authors: wu yl. J Hematol Oncol. 2019 Apr 25;12(1):45. doi: 10.1186/s13045-019-0731-8. J Hematol Oncol. 2019. PMID: 31023335 Free PMC article. Review.
1,630 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page
Feedback